Dimension Therapeutics Inc. (DMTX) Stock Price Down 5%
Dimension Therapeutics Inc. (NASDAQ:DMTX)’s share price dropped 5% on Wednesday . The stock traded as low as $9.01 and last traded at $9.01, with a volume of 70,105 shares trading hands. The stock had previously closed at $9.48.
DMTX has been the subject of several recent research reports. Jefferies Group set a $12.00 target price on shares of Dimension Therapeutics and gave the company a “buy” rating in a report on Monday, September 12th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Dimension Therapeutics in a report on Wednesday, June 22nd. Canaccord Genuity set a $20.00 target price on shares of Dimension Therapeutics and gave the company a “buy” rating in a report on Thursday, August 11th. Zacks Investment Research lowered shares of Dimension Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Finally, Chardan Capital set a $10.00 target price on shares of Dimension Therapeutics and gave the company a “hold” rating in a report on Sunday, August 21st. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Dimension Therapeutics presently has a consensus rating of “Buy” and an average price target of $17.19.
The stock’s 50 day moving average price is $7.14 and its 200-day moving average price is $7.45. The company’s market cap is $227.26 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/dimension-therapeutics-inc-dmtx-stock-price-down-5.html
Dimension Therapeutics (NASDAQ:DMTX) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. Dimension Therapeutics had a negative net margin of 459.47% and a negative return on equity of 66.58%. Equities analysts expect that Dimension Therapeutics Inc. will post ($1.91) earnings per share for the current fiscal year.
Large investors have recently bought and sold shares of the stock. Teachers Advisors Inc. increased its stake in Dimension Therapeutics by 224.3% in the second quarter. Teachers Advisors Inc. now owns 19,204 shares of the company’s stock valued at $115,000 after buying an additional 13,283 shares during the last quarter. Highbridge Capital Management LLC bought a new stake in Dimension Therapeutics during the second quarter valued at approximately $123,000. Bridgeway Capital Management Inc. bought a new stake in Dimension Therapeutics during the second quarter valued at approximately $128,000. A.R.T. Advisors LLC bought a new stake in Dimension Therapeutics during the second quarter valued at approximately $134,000. Finally, California State Teachers Retirement System boosted its stake in Dimension Therapeutics by 113.2% in the second quarter. California State Teachers Retirement System now owns 25,634 shares of the company’s stock valued at $154,000 after buying an additional 13,610 shares during the period. 85.80% of the stock is owned by institutional investors and hedge funds.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.